# Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy

> **NCT00079859** · PHASE2 · TERMINATED · sponsor: **Medical Research Laboratories International** · enrollment: 120 (—)

## Conditions studied

- Familial Hypercholesterolemia

## Interventions

- **DRUG:** Implitapide

## Key facts

- **NCT ID:** NCT00079859
- **Lead sponsor:** Medical Research Laboratories International
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-10
- **Primary completion:** —
- **Final completion:** 2005-04
- **Target enrollment:** 120 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00079859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00079859, "Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00079859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*